PURPOSE: Clinical studies in diabetic patients have demonstrated that there is a high incidence of complications in distal tibia and ankle fracture treatments. One strategy to mitigate issues with wound healing and infection in diabetic patients is to use a percutaneous technique in which autologous, bone marrow-derived, concentrated cells are injected at the site of non-unions. METHODS: Eighty-six ankle non-union in diabetic patients were treated with bone marrow mesenchymal stem cells (BM-MSCs) delivered in an autologous bone marrow concentrate (BMC). Clinical outcomes of the 86 diabetic non-union patients treated with BMC were compared with 86 diabetic matched non-unions treated with a standard bone iliac crest autograft. RESULTS: Treatment with BMC promoted non-union healing in 70 among 86 diabetic patients (82.1 %) with a low number of complications. Of the 86 diabetic patients treated with iliac bone graft, 53 (62.3 %) had healing; major complications were observed: 5 amputations, 11 osteonecroses of the fracture wound edge and 17 infections. CONCLUSIONS: In diabetic patients with ankle non-unions, treatment with BM-MSCs from bone marrow concentrate may be preferable in view of the high risks of major complications after open surgery and iliac bone grafting, and improved healing rates compared with standard iliac bone autograft treatment.
PURPOSE: Clinical studies in diabeticpatients have demonstrated that there is a high incidence of complications in distal tibia and ankle fracture treatments. One strategy to mitigate issues with wound healing and infection in diabeticpatients is to use a percutaneous technique in which autologous, bone marrow-derived, concentrated cells are injected at the site of non-unions. METHODS: Eighty-six ankle non-union in diabeticpatients were treated with bone marrow mesenchymal stem cells (BM-MSCs) delivered in an autologous bone marrow concentrate (BMC). Clinical outcomes of the 86 diabetic non-union patients treated with BMC were compared with 86 diabetic matched non-unions treated with a standard bone iliac crest autograft. RESULTS: Treatment with BMC promoted non-union healing in 70 among 86 diabeticpatients (82.1 %) with a low number of complications. Of the 86 diabeticpatients treated with iliac bone graft, 53 (62.3 %) had healing; major complications were observed: 5 amputations, 11 osteonecroses of the fracture wound edge and 17 infections. CONCLUSIONS: In diabeticpatients with ankle non-unions, treatment with BM-MSCs from bone marrow concentrate may be preferable in view of the high risks of major complications after open surgery and iliac bone grafting, and improved healing rates compared with standard iliac bone autograft treatment.
Authors: Rayyan A Kayal; Dimitris Tsatsas; Megan A Bauer; Brian Allen; Maisa O Al-Sebaei; Sanjeev Kakar; Cataldo W Leone; Elise F Morgan; Louis C Gerstenfeld; Thomas A Einhorn; Dana T Graves Journal: J Bone Miner Res Date: 2007-04 Impact factor: 6.741
Authors: M Chochola; R Pytlík; P Kobylka; L Skalická; L Kideryová; S Beran; P Varejka; S Jirát; J Køivánek; M Aschermann; A Linhart Journal: Int Angiol Date: 2008-08 Impact factor: 2.789
Authors: Philippe Hernigou; Matthieu Trousselier; François Roubineau; Charlie Bouthors; Nathalie Chevallier; Helene Rouard; Charles Henri Flouzat-Lachaniette Journal: Int Orthop Date: 2016-03-01 Impact factor: 3.075
Authors: Olga Wittig; Egidio Romano; Cesar González; Dylana Diaz-Solano; Maria Elena Marquez; Pedro Tovar; Rodolfo Aoun; Jose E Cardier Journal: Int Orthop Date: 2016-03-16 Impact factor: 3.075
Authors: Bishoy N Saad; David Zurita; Deborah J Li; Hannah Dailey; Richard S Yoon; Frank A Liporace Journal: Indian J Orthop Date: 2021-06-03 Impact factor: 1.033
Authors: Charles Henri Flouzat-Lachaniette; Clemence Heyberger; Charlie Bouthors; François Roubineau; Nathalie Chevallier; Helene Rouard; Philippe Hernigou Journal: Int Orthop Date: 2015-11-17 Impact factor: 3.075
Authors: Carlos Marin; Frank P Luyten; Bart Van der Schueren; Greet Kerckhofs; Katleen Vandamme Journal: Front Endocrinol (Lausanne) Date: 2018-01-24 Impact factor: 5.555